

Review of: "[Research Note] Semaglutide, a GLP-1 Agonist Like Ozempic, and Its Potential Role as a Preventive Anti-Cancer Agent"

Stéphanie Grandemange¹

¹ University of Lorraine

Potential competing interests: No potential competing interests to declare.

This note is really interesting, but the authors should subdivide it into parts and add a few explanatory schemes to increase comprehension and readability. At least a graphical abstract of GLP-1 agonists' effects could be appropriate. The authors should also clarify the cancer type they mentioned all along the manuscript because it's sometimes unclear.